ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
ProMIS Neurosciences (Nasdaq: PMN), a clinical-stage biotechnology company specializing in antibody therapeutics for neurodegenerative diseases, announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. CEO Neil Warma will engage in a fireside chat on November 13, 2024, at 10:00 a.m. ET in Boston, MA. The company focuses on targeting toxic misfolded proteins in conditions like Alzheimer's disease, ALS, and multiple system atrophy. A live webcast will be available on the company's website and remain accessible for at least 30 days after the event.
ProMIS Neurosciences (Nasdaq: PMN), un'azienda biotecnologica in fase clinica che si specializza in terapie anticorpali per le malattie neurodegenerative, ha annunciato la sua partecipazione alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim. Il CEO Neil Warma parteciperà a una chiacchierata informale il 13 novembre 2024, alle 10:00 ora orientale, a Boston, MA. L'azienda si concentra sul targeting delle proteine tossiche mal ripiegate in condizioni come la malattia di Alzheimer, la SLA e l'atrofia multi-sistemica. Una diretta web sarà disponibile sul sito dell'azienda e resterà accessibile per almeno 30 giorni dopo l'evento.
ProMIS Neurosciences (Nasdaq: PMN), una compañía de biotecnología en etapa clínica especializada en terapias con anticuerpos para enfermedades neurodegenerativas, anunció su participación en la Conferencia de Innovación en Salud Inaugural de Guggenheim. El CEO Neil Warma participará en un chat informal el 13 de noviembre de 2024, a las 10:00 a.m. ET en Boston, MA. La compañía se enfoca en dirigir las proteínas tóxicas mal plegadas en condiciones como la enfermedad de Alzheimer, ELA y la atrofia multisistémica. Una transmisión en vivo estará disponible en el sitio web de la empresa y permanecerá accesible por al menos 30 días después del evento.
ProMIS Neurosciences (Nasdaq: PMN), 신경퇴행성 질환을 위한 항체 치료제를 전문으로 하는 임상 단계의 생명공학 회사가 구겐하임의 첫 번째 의료 혁신 컨퍼런스에 참여한다고 발표했습니다. CEO Neil Warma는 2024년 11월 13일 오전 10시(동부 표준 시각) 보스턴 MA에서 대담을 진행할 예정입니다. 이 회사는 알츠하이머병, ALS, 다계통 위축증과 같은 상태에서 독성의 잘못 접힌 단백질을 타겟으로 하는 데 중점을 두고 있습니다. 생중계는 회사 웹사이트에서 제공되며, 행사 종료 후 최소 30일 동안 이용할 수 있습니다.
ProMIS Neurosciences (Nasdaq: PMN), une société biopharmaceutique en phase clinique spécialisée dans les thérapies par anticorps pour les maladies neurodégénératives, a annoncé sa participation à la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim. Le PDG Neil Warma participera à une discussion informelle le 13 novembre 2024 à 10 h (heure de l'Est) à Boston, MA. La société se concentre sur la cible des protéines toxiques mal pliées dans des conditions telles que la maladie d'Alzheimer, la SLA et l'atrophie multisystémique. Un streaming en direct sera disponible sur le site web de l'entreprise et restera accessible pendant au moins 30 jours après l'événement.
ProMIS Neurosciences (Nasdaq: PMN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das auf Antikörpertherapeutika für neurodegenerative Erkrankungen spezialisiert ist, hat seine Teilnahme an der Ersten Gesundheitsinnovationskonferenz von Guggenheim bekannt gegeben. CEO Neil Warma wird am 13. November 2024 um 10:00 Uhr ET in Boston, MA, an einem informellen Gespräch teilnehmen. Das Unternehmen konzentriert sich auf die Ausrichtung auf toxisch fehlgefaltete Proteine bei Erkrankungen wie Alzheimer, ALS und multiple Systematrophie. Eine Live-Übertragung wird auf der Unternehmenswebsite verfügbar sein und mindestens 30 Tage nach der Veranstaltung zugänglich bleiben.
- None.
- None.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024 at 10:00 a.m. ET in Boston, MA.
A live webcast of the fireside chat may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company’s lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic Aβ oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to be is the only antibody to selectively bind oligomers, which is expected to support better safety and efficacy. PMN 310 has successfully completed a Phase 1a clinical study and ProMIS expects to initiate a Phase 1b clinical trial in AD patients by year end 2024. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.
For further information:
Visit us at www.promisneurosciences.com.
Please submit media inquiries to info@promisneurosciences.com.
For Investor Relations, please contact:
Precision AQ (formerly Stern IR)
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200
FAQ
When is ProMIS Neurosciences (PMN) presenting at Guggenheim's Healthcare Innovation Conference?
What diseases does ProMIS Neurosciences (PMN) target with their therapeutics?
How can investors watch ProMIS Neurosciences' (PMN) Guggenheim conference presentation?
